Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Henrik Jensen

Showing results (1-10 of 114) with videos related to

Pageof 12
Sort By:
The Lancet. Oncology|December 24, 2011
Biliary-tract cancer: improving therapy by adding molecularly targeted agentsLars Henrik Jensen
The Lancet. Digital Health|June 16, 2025
Video in the clinic: advancing care for patients, professionals, and the planetLars Henrik Jensen
Expert Opinion on Investigational Drugs|January 20, 2016
Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancerLars Henrik Jensen
The Lancet. Oncology|August 14, 2025
Breaking the patient-reported outcome code in KRAS<sup>G12C</sup>-mutated colorectal cancer: clinical interpretation of CodeBreaK 300Lars Henrik Jensen
Ugeskrift for Laeger|November 13, 2018
[Medical treatment of patients with colorectal cancer in Denmark]Lars Henrik Jensen
Expert Review of Anticancer Therapy|April 21, 2011
Combining biological agents and chemotherapy in the treatment of cholangiocarcinomaLars Henrik Jensen, Anders Jakobsen
Ugeskrift for Laeger|March 18, 2014
[Systemic treatment of biliary tract cancer]Lars Henrik Jensen, Ole Larsen
International Journal of Molecular Sciences|January 25, 2025
Dysbiosis-NK Cell Crosstalk in Pancreatic Cancer: Toward a Unified Biomarker Signature for Improved Clinical OutcomesSara Fanijavadi, Lars Henrik Jensen
Ugeskrift for Laeger|September 2, 2015
[Fast identification of febrile neutropenia improves the outcome]Sofia Johansson, Lars Henrik Jensen
International Journal of Molecular Sciences|January 25, 2025
Targeting Triple NK Cell Suppression Mechanisms: A Comprehensive Review of Biomarkers in Pancreatic Cancer TherapySara Fanijavadi, Mads Thomassen, Lars Henrik Jensen
Pageof 12

Showing results (1-10 of 114) with videos related to

Sort By:
Pageof 12
The Lancet. Oncology|December 24, 2011
Biliary-tract cancer: improving therapy by adding molecularly targeted agentsLars Henrik Jensen
The Lancet. Digital Health|June 16, 2025
Video in the clinic: advancing care for patients, professionals, and the planetLars Henrik Jensen
Expert Opinion on Investigational Drugs|January 20, 2016
Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancerLars Henrik Jensen
The Lancet. Oncology|August 14, 2025
Breaking the patient-reported outcome code in KRAS<sup>G12C</sup>-mutated colorectal cancer: clinical interpretation of CodeBreaK 300Lars Henrik Jensen
Ugeskrift for Laeger|November 13, 2018
[Medical treatment of patients with colorectal cancer in Denmark]Lars Henrik Jensen
Expert Review of Anticancer Therapy|April 21, 2011
Combining biological agents and chemotherapy in the treatment of cholangiocarcinomaLars Henrik Jensen, Anders Jakobsen
Ugeskrift for Laeger|March 18, 2014
[Systemic treatment of biliary tract cancer]Lars Henrik Jensen, Ole Larsen
International Journal of Molecular Sciences|January 25, 2025
Dysbiosis-NK Cell Crosstalk in Pancreatic Cancer: Toward a Unified Biomarker Signature for Improved Clinical OutcomesSara Fanijavadi, Lars Henrik Jensen
Ugeskrift for Laeger|September 2, 2015
[Fast identification of febrile neutropenia improves the outcome]Sofia Johansson, Lars Henrik Jensen
International Journal of Molecular Sciences|January 25, 2025
Targeting Triple NK Cell Suppression Mechanisms: A Comprehensive Review of Biomarkers in Pancreatic Cancer TherapySara Fanijavadi, Mads Thomassen, Lars Henrik Jensen
Pageof 12